Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma.
Cytotoxic lymphocyte
Lung adenocarcinoma
Lymph node metastasis
Tertiary lymphoid structure
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
13
11
2020
accepted:
07
01
2022
medline:
22
5
2023
pubmed:
24
1
2023
entrez:
23
1
2023
Statut:
ppublish
Résumé
Ectopic lymphoid formations are called tertiary lymphoid structures (TLSs). TLSs in cancer have been reported to be associated with good prognosis and immunotherapy response. However, the relationship between TLSs and lymph node (LN) metastasis is unclear. We analyzed 218 patients with radically resected lung adenocarcinoma. TLSs were defined as the overlap of T cell zone and B cell zone. Granzyme B The mature TLS group was associated with significantly lower frequency of LN metastasis (P < 0.0001) and early cancer stage (P = 0.0049). The mature TLS group had significantly more CD8 Mature TLSs were associated with an increased number of cytotoxic lymphocytes in draining LNs, a lower frequency of LN metastasis, and favorable outcomes. Mature TLSs may support antitumor immunity by lymphocyte activation.
Sections du résumé
BACKGROUND
BACKGROUND
Ectopic lymphoid formations are called tertiary lymphoid structures (TLSs). TLSs in cancer have been reported to be associated with good prognosis and immunotherapy response. However, the relationship between TLSs and lymph node (LN) metastasis is unclear.
METHODS
METHODS
We analyzed 218 patients with radically resected lung adenocarcinoma. TLSs were defined as the overlap of T cell zone and B cell zone. Granzyme B
RESULTS
RESULTS
The mature TLS group was associated with significantly lower frequency of LN metastasis (P < 0.0001) and early cancer stage (P = 0.0049). The mature TLS group had significantly more CD8
CONCLUSION
CONCLUSIONS
Mature TLSs were associated with an increased number of cytotoxic lymphocytes in draining LNs, a lower frequency of LN metastasis, and favorable outcomes. Mature TLSs may support antitumor immunity by lymphocyte activation.
Identifiants
pubmed: 36688996
doi: 10.1007/s00262-022-03353-8
pii: 10.1007/s00262-022-03353-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1823-1834Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR, Investigators K (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833. https://doi.org/10.1056/NEJMoa1606774
doi: 10.1056/NEJMoa1606774
pubmed: 27718847
Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC, Investigators K (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378(22):2078–2092. https://doi.org/10.1056/NEJMoa1801005
doi: 10.1056/NEJMoa1801005
pubmed: 29658856
Bruno TC (2020) New predictors for immunotherapy responses sharpen our view of the tumour microenvironment. Nature 577(7791):474–476. https://doi.org/10.1038/d41586-019-03943-0
doi: 10.1038/d41586-019-03943-0
pubmed: 31965091
pmcid: 7523515
Dieu-Nosjean MC, Goc J, Giraldo NA, Sautes-Fridman C, Fridman WH (2014) Tertiary lymphoid structures in cancer and beyond. Trends Immunol 35(11):571–580. https://doi.org/10.1016/j.it.2014.09.006
doi: 10.1016/j.it.2014.09.006
pubmed: 25443495
Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, Lebecque S, Fridman WH, Cadranel J (2008) Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 26(27):4410–4417. https://doi.org/10.1200/JCO.2007.15.0284
doi: 10.1200/JCO.2007.15.0284
pubmed: 18802153
Colbeck EJ, Ager A, Gallimore A, Jones GW (2017) Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in Disease? Front Immunol 8:1830. https://doi.org/10.3389/fimmu.2017.01830
doi: 10.3389/fimmu.2017.01830
pubmed: 29312327
pmcid: 5742143
Gu-Trantien C, Migliori E, Buisseret L, de Wind A, Brohee S, Garaud S, Noel G, Dang Chi VL, Lodewyckx JN, Naveaux C, Duvillier H, Goriely S, Larsimont D, Willard-Gallo K (2017) CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer. JCI Insight. https://doi.org/10.1172/jci.insight.91487
doi: 10.1172/jci.insight.91487
pubmed: 28570278
pmcid: 5453706
Nayar S, Campos J, Smith CG, Iannizzotto V, Gardner DH, Mourcin F, Roulois D, Turner J, Sylvestre M, Asam S, Glaysher B, Bowman SJ, Fearon DT, Filer A, Tarte K, Luther SA, Fisher BA, Buckley CD, Coles MC, Barone F (2019) Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology. Proc Natl Acad Sci U S A 116(27):13490–13497. https://doi.org/10.1073/pnas.1905301116
doi: 10.1073/pnas.1905301116
pubmed: 31213547
pmcid: 6613169
Lin L, Hu X, Zhang H, Hu H (2019) Tertiary lymphoid organs in cancer immunology: mechanisms and the new strategy for immunotherapy. Front Immunol 10:1398. https://doi.org/10.3389/fimmu.2019.01398
doi: 10.3389/fimmu.2019.01398
pubmed: 31281318
pmcid: 6596321
Nerviani A, Pitzalis C (2018) Role of chemokines in ectopic lymphoid structures formation in autoimmunity and cancer. J Leukoc Biol 104(2):333–341. https://doi.org/10.1002/JLB.3MR0218-062R
doi: 10.1002/JLB.3MR0218-062R
pubmed: 29947426
Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, Lepelley A, Becht E, Katsahian S, Bizouard G, Validire P, Damotte D, Alifano M, Magdeleinat P, Cremer I, Teillaud JL, Fridman WH, Sautes-Fridman C, Dieu-Nosjean MC (2014) Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med 189(7):832–844. https://doi.org/10.1164/rccm.201309-1611OC
doi: 10.1164/rccm.201309-1611OC
pubmed: 24484236
Hiraoka N, Ino Y, Yamazaki-Itoh R, Kanai Y, Kosuge T, Shimada K (2015) Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br J Cancer 112(11):1782–1790. https://doi.org/10.1038/bjc.2015.145
doi: 10.1038/bjc.2015.145
pubmed: 25942397
pmcid: 4647237
Koti M, Xu AS, Ren KYM, Visram K, Ren R, Berman DM, Siemens DR (2017) Tertiary lymphoid structures associate with tumour stage in urothelial bladder cancer. Bladder Cancer 3(4):259–267. https://doi.org/10.3233/BLC-170120
doi: 10.3233/BLC-170120
pubmed: 29152550
pmcid: 5676768
Posch F, Silina K, Leibl S, Mundlein A, Moch H, Siebenhuner A, Samaras P, Riedl J, Stotz M, Szkandera J, Stoger H, Pichler M, Stupp R, van den Broek M, Schraml P, Gerger A, Petrausch U, Winder T (2018) Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. Oncoimmunology 7(2):e1378844. https://doi.org/10.1080/2162402X.2017.1378844
doi: 10.1080/2162402X.2017.1378844
pubmed: 29416939
Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautes-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA (2020) B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577(7791):549–555. https://doi.org/10.1038/s41586-019-1922-8
doi: 10.1038/s41586-019-1922-8
pubmed: 31942075
pmcid: 8762581
Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, Johansson I, Phung B, Harbst K, Vallon-Christersson J, van Schoiack A, Lovgren K, Warren S, Jirstrom K, Olsson H, Pietras K, Ingvar C, Isaksson K, Schadendorf D, Schmidt H, Bastholt L, Carneiro A, Wargo JA, Svane IM, Jonsson G (2020) Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577(7791):561–565. https://doi.org/10.1038/s41586-019-1914-8
doi: 10.1038/s41586-019-1914-8
pubmed: 31942071
Petitprez F, de Reynies A, Keung EZ, Chen TW, Sun CM, Calderaro J, Jeng YM, Hsiao LP, Lacroix L, Bougouin A, Moreira M, Lacroix G, Natario I, Adam J, Lucchesi C, Laizet YH, Toulmonde M, Burgess MA, Bolejack V, Reinke D, Wani KM, Wang WL, Lazar AJ, Roland CL, Wargo JA, Italiano A, Sautes-Fridman C, Tawbi HA, Fridman WH (2020) B cells are associated with survival and immunotherapy response in sarcoma. Nature 577(7791):556–560. https://doi.org/10.1038/s41586-019-1906-8
doi: 10.1038/s41586-019-1906-8
pubmed: 31942077
Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, Askin FB, Niknafs N, Smith KN, Velez MJ, Sauter JL, Isbell JM, Jones DR, Battafarano RJ, Yang SC, Danilova L, Wolchok JD, Topalian SL, Velculescu VE, Pardoll DM, Brahmer JR, Hellmann MD, Chaft JE, Cimino-Mathews A, Taube JM (2018) Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol 29(8):1853–1860. https://doi.org/10.1093/annonc/mdy218
doi: 10.1093/annonc/mdy218
pubmed: 29982279
pmcid: 6096736
Sautes-Fridman C, Petitprez F, Calderaro J, Fridman WH (2019) Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer 19(6):307–325. https://doi.org/10.1038/s41568-019-0144-6
doi: 10.1038/s41568-019-0144-6
pubmed: 31092904
Chamoto K, Chowdhury PS, Kumar A, Sonomura K, Matsuda F, Fagarasan S, Honjo T (2017) Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc Natl Acad Sci U S A 114(5):E761–E770. https://doi.org/10.1073/pnas.1620433114
doi: 10.1073/pnas.1620433114
pubmed: 28096382
pmcid: 5293087
Takada K, Okamoto T, Shoji F, Shimokawa M, Akamine T, Takamori S, Katsura M, Suzuki Y, Fujishita T, Toyokawa G, Morodomi Y, Okano S, Oda Y, Maehara Y (2016) Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma. J Thorac Oncol 11(11):1879–1890. https://doi.org/10.1016/j.jtho.2016.06.006
doi: 10.1016/j.jtho.2016.06.006
pubmed: 27346415
Figenschau SL, Fismen S, Fenton KA, Fenton C, Mortensen ES (2015) Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients. BMC Cancer 15:101. https://doi.org/10.1186/s12885-015-1116-1
doi: 10.1186/s12885-015-1116-1
pubmed: 25884667
pmcid: 4357183
Trajkovski G, Ognjenovic L, Karadzov Z, Jota G, Hadzi-Manchev D, Kostovski O, Volcevski G, Trajkovska V, Nikolova D, Spasevska L, Janevska V, Janevski V (2018) Tertiary lymphoid structures in colorectal cancers and their prognostic value. Open Access Maced J Med Sci 6(10):1824–1828. https://doi.org/10.3889/oamjms.2018.341
doi: 10.3889/oamjms.2018.341
pubmed: 30455756
pmcid: 6236051
Dammeijer F, van Gulijk M, Mulder EE, Lukkes M, Klaase L, van den Bosch T, van Nimwegen M, Lau SP, Latupeirissa K, Schetters S, van Kooyk Y, Boon L, Moyaart A, Mueller YM, Katsikis PD, Eggermont AM, Vroman H, Stadhouders R, Hendriks RW, Thusen JV, Grunhagen DJ, Verhoef C, van Hall T, Aerts JG (2020) The PD-1/PD-L1-checkpoint restrains T cell Immunity in tumor-draining lymph nodes. Cancer Cell. https://doi.org/10.1016/j.ccell.2020.09.001
doi: 10.1016/j.ccell.2020.09.001
pubmed: 33007259
Engelhard VH, Rodriguez AB, Mauldin IS, Woods AN, Peske JD, Slingluff CL Jr (2018) Immune cell infiltration and Tertiary lymphoid structures as determinants of antitumor immunity. J Immunol 200(2):432–442. https://doi.org/10.4049/jimmunol.1701269
doi: 10.4049/jimmunol.1701269
pubmed: 29311385
Pesce S, Moretta L, Moretta A, Marcenaro E (2016) Human NK cell subsets redistribution in pathological conditions: a role for CCR7 receptor. Front Immunol 7:414. https://doi.org/10.3389/fimmu.2016.00414
doi: 10.3389/fimmu.2016.00414
pubmed: 27774094
pmcid: 5053980
de Chaisemartin L, Goc J, Damotte D, Validire P, Magdeleinat P, Alifano M, Cremer I, Fridman WH, Sautes-Fridman C, Dieu-Nosjean MC (2011) Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res 71(20):6391–6399. https://doi.org/10.1158/0008-5472.CAN-11-0952
doi: 10.1158/0008-5472.CAN-11-0952
pubmed: 21900403
Guedj K, Khallou-Laschet J, Clement M, Morvan M, Gaston AT, Fornasa G, Dai J, Gervais-Taurel M, Eberl G, Michel JB, Caligiuri G, Nicoletti A (2014) M1 macrophages act as LTbetaR-independent lymphoid tissue inducer cells during atherosclerosis-related lymphoid neogenesis. Cardiovasc Res 101(3):434–443. https://doi.org/10.1093/cvr/cvt263
doi: 10.1093/cvr/cvt263
pubmed: 24272771
Germain C, Gnjatic S, Dieu-Nosjean MC (2015) Tertiary lymphoid structure-associated B cells are key players in anti-tumor immunity. Front Immunol 6:67. https://doi.org/10.3389/fimmu.2015.00067
doi: 10.3389/fimmu.2015.00067
pubmed: 25755654
pmcid: 4337382
Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, de Chaisemartin L, Ouakrim H, Becht E, Alifano M, Validire P, Remark R, Hammond SA, Cremer I, Damotte D, Fridman WH, Sautes-Fridman C, Dieu-Nosjean MC (2014) Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res 74(3):705–715. https://doi.org/10.1158/0008-5472.CAN-13-1342
doi: 10.1158/0008-5472.CAN-13-1342
pubmed: 24366885
Zeng DQ, Yu YF, Ou QY, Li XY, Zhong RZ, Xie CM, Hu QG (2016) Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer. Oncotarget 7(12):13765–13781. https://doi.org/10.18632/oncotarget.7282
doi: 10.18632/oncotarget.7282
pubmed: 26871598
pmcid: 4924677
Silina K, Soltermann A, Attar FM, Casanova R, Uckeley ZM, Thut H, Wandres M, Isajevs S, Cheng P, Curioni-Fontecedro A, Foukas P, Levesque MP, Moch H, Line A, van den Broek M (2018) Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. Cancer Res 78(5):1308–1320. https://doi.org/10.1158/0008-5472.CAN-17-1987
doi: 10.1158/0008-5472.CAN-17-1987
pubmed: 29279354
Solinas C, Garaud S, De Silva P, Boisson A, Van den Eynden G, de Wind A, Risso P, Rodrigues Vitoria J, Richard F, Migliori E, Noel G, Duvillier H, Craciun L, Veys I, Awada A, Detours V, Larsimont D, Piccart-Gebhart M, Willard-Gallo K (2017) Immune checkpoint molecules on tumor-infiltrating lymphocytes and their association with tertiary lymphoid structures in human breast cancer. Front Immunol 8:1412. https://doi.org/10.3389/fimmu.2017.01412
doi: 10.3389/fimmu.2017.01412
pubmed: 29163490
pmcid: 5670348
Collins M, Ling V, Carreno BM (2005) The B7 family of immune-regulatory ligands. Genome Biol 6(6):223. https://doi.org/10.1186/gb-2005-6-6-223
doi: 10.1186/gb-2005-6-6-223
pubmed: 15960813
pmcid: 1175965
Hodge G, Barnawi J, Jurisevic C, Moffat D, Holmes M, Reynolds PN, Jersmann H, Hodge S (2014) Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-gamma by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells. Clin Exp Immunol 178(1):79–85. https://doi.org/10.1111/cei.12392
doi: 10.1111/cei.12392
pubmed: 24894428
pmcid: 4360197
Johansson-Percival A, He B, Li ZJ, Kjellen A, Russell K, Li J, Larma I, Ganss R (2017) De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Nat Immunol 18(11):1207–1217. https://doi.org/10.1038/ni.3836
doi: 10.1038/ni.3836
pubmed: 28892469
Martin C, Thevenot G, Danel S, Chapron J, Tazi A, Macey J, Dusser DJ, Fajac I, Burgel PR (2011) Pseudomonas aeruginosa induces vascular endothelial growth factor synthesis in airway epithelium in vitro and in vivo. Eur Respir J 38(4):939–946. https://doi.org/10.1183/09031936.00134910
doi: 10.1183/09031936.00134910
pubmed: 21436353